8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer.

          Electronic supplementary material

          The online version of this article (doi:10.1007/s11030-016-9692-9) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          The productivity crisis in pharmaceutical R&D.

          Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, we examine the decline of R&D productivity in pharmaceuticals in the past two decades and its determinants. We show that this decline is associated with an increasing concentration of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. We also investigate the potential variations in productivity with regard to the regional location of companies and find that although companies based in the United States and Europe differ in the composition of their R&D portfolios, there is no evidence of any productivity gap.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Virtual screening: an endless staircase?

            Computational chemistry--in particular, virtual screening--can provide valuable contributions in hit- and lead-compound discovery. Numerous software tools have been developed for this purpose. However, despite the applicability of virtual screening technology being well established, it seems that there are relatively few examples of drug discovery projects in which virtual screening has been the key contributor. Has virtual screening reached its peak? If not, what aspects are limiting its potential at present, and how can significant progress be made in the future?
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The influence of lipophilicity in drug discovery and design.

              The role of lipophilicity in drug discovery and design is a critical one. Lipophilicity is a key physicochemical property that plays a crucial role in determining ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and the overall suitability of drug candidates. There is increasing evidence to suggest that control of physicochemical properties such as lipophilicity, within a defined optimal range, can improve compound quality and the likelihood of therapeutic success. This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years. A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochemical properties associated with ADMET throughout drug optimization. Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indices, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.
                Bookmark

                Author and article information

                Contributors
                +44 208 331 8323 , j.r.everett@greenwich.ac.uk
                Journal
                Mol Divers
                Mol. Divers
                Molecular Diversity
                Springer International Publishing (Cham )
                1381-1991
                1573-501X
                8 September 2016
                8 September 2016
                2016
                : 20
                : 4
                : 789-803
                Affiliations
                [1 ]Pfizer Worldwide Research and Development, Groton, CT USA
                [2 ]Pfizer Worldwide Research & Development, Sandwich, Kent UK
                [3 ]Imperial College, London, UK
                [4 ]Scitegrity Ltd, Discovery Park, Sandwich, Kent UK
                [5 ]University of Greenwich, Chatham Maritime, Kent UK
                [6 ]JL Consulting, Deal, Kent UK
                [7 ]Eli Lilly & Company, Indianapolis, IN USA
                [8 ]Sandexis Medicinal Chemistry Ltd, Canterbury, Kent UK
                [9 ]RES Consulting, San Francisco Bay, CA USA
                [10 ]Ipsen, Slough, Berkshire UK
                Author information
                http://orcid.org/0000-0003-1550-4482
                Article
                9692
                10.1007/s11030-016-9692-9
                5055576
                27631533
                21f2813c-ce8e-42b0-a8d0-eaec66d82a05
                © The Author(s) 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 13 April 2016
                : 29 July 2016
                Categories
                Original Article
                Custom metadata
                © Springer International Publishing Switzerland 2016

                Molecular biology
                rule of 40,ro40,high-throughput screening (hts),plate-based,diversity,subset,screening file,2nd generation,lead discovery

                Comments

                Comment on this article